Enliven Therapeutics, Inc. (ELVN) Insider Ownership

Historic Insider Ownership Trends

As of March 23, 2026, the three largest insider holders of ELVN are Rishi Gupta (Director, 7.66Mn shares), Advisors Llc Orbimed (Director, 7.66Mn shares), David P Bonita (Director, 4.20Mn shares).

Top Direct Holders

Insider ownership data is derived from the last 60 months of Form 4 SEC filings.
Holder Position Shares (Direct) Shares (Indirect) Report Date
Rishi Gupta 0 7,663,349 20 May, 2024
Advisors Llc Orbimed 0 7,663,349 20 May, 2024
David P Bonita 0 4,199,068 23 Jul, 2021
Enterprise Associates 14, L.P. New 2,611,050 0 07 Apr, 2022
Mark Chin 0 2,344,072 27 Jul, 2021
Capital Management, L.P. Ra 0 2,122,465 27 Feb, 2023
Braden Michael Leonard 0 1,767,774 05 Jan, 2023
Capital Lp Commodore 0 1,448,640 27 Feb, 2023
Andrew J. Schwab 0 960,383 27 Feb, 2023
Samuel Kintz President And Ceo 0 890,392 19 Nov, 2025
Joseph P Lyssikatos Chief Scientific Officer 0 740,188 10 Feb, 2026
Partners Vi, Llc 5Am 0 635,341 16 Feb, 2024
Braden Michael Leonard 230,000 0 30 Dec, 2022
David M Mott 229,224 0 23 Feb, 2022
Anish Patel Chief Operating Officer 0 215,011 13 Jan, 2026
Richard A. Heyman 123,673 0 22 Oct, 2024
Jake Bauer 87,372 0 27 Feb, 2023
Benjamin Hohl Chief Financial Officer 51,000 0 10 Mar, 2026
Lori Anne Kunkel 30,712 0 19 Dec, 2025
Michael Gray Cfo Coo 27,610 0 22 Feb, 2023
Helen Louise Collins Chief Medical Officer 25,000 0 19 Mar, 2026
Helen Louise Collins Chief Medical Officer 25,000 0 11 Mar, 2026
Richard A. Heyman 0 22,647 19 Feb, 2026
Rahul D. Ballal 22,341 0 10 Oct, 2024
Anish Patel Chief Operating Officer 20,000 0 17 Feb, 2026
Joseph P Lyssikatos Chief Scientific Officer 18,750 0 17 Feb, 2026

* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.

Recent Insider Transactions

Detailed insider trading activity based on Form 4 SEC filings.
Download Data
Transaction Date Insider Name Security Class Transaction Type Shares Traded Price Shares Remaining Ownership Code
17 Mar, 2026 Helen Louise Collins Common Stock A 5,000 $2.48 30,000 D M
17 Mar, 2026 Helen Louise Collins Common Stock D 5,000 $27.76 25,000 D S
17 Mar, 2026 Helen Louise Collins Stock Option (right to buy) D 5,000 $0.00 176,268 D M
09 Mar, 2026 Helen Louise Collins Common Stock A 29,871 $2.48 54,871 D M
09 Mar, 2026 Helen Louise Collins Common Stock A 29,871 $2.48 54,871 D M
09 Mar, 2026 Helen Louise Collins Common Stock D 29,871 $30.02 25,000 D S
09 Mar, 2026 Helen Louise Collins Common Stock D 29,871 $30.02 25,000 D S
10 Mar, 2026 Helen Louise Collins Common Stock A 10,129 $2.48 35,129 D M
10 Mar, 2026 Helen Louise Collins Common Stock A 10,129 $2.48 35,129 D M
10 Mar, 2026 Helen Louise Collins Common Stock D 10,129 $30.19 25,000 D S
10 Mar, 2026 Helen Louise Collins Common Stock D 10,129 $30.19 25,000 D S
09 Mar, 2026 Helen Louise Collins Stock Option (right to buy) D 29,871 $0.00 191,397 D M
09 Mar, 2026 Helen Louise Collins Stock Option (right to buy) D 29,871 $0.00 191,397 D M
10 Mar, 2026 Helen Louise Collins Stock Option (right to buy) D 10,129 $0.00 181,268 D M
10 Mar, 2026 Helen Louise Collins Stock Option (right to buy) D 10,129 $0.00 181,268 D M
06 Mar, 2026 Benjamin Hohl Common Stock D 10,000 $29.58 51,000 D S
17 Feb, 2026 Richard A. Heyman Common Stock D 1,230 $26.18 22,647 I S
17 Feb, 2026 Helen Louise Collins Common Stock A 45,000 $2.48 70,000 D M
17 Feb, 2026 Helen Louise Collins Common Stock A 45,000 $2.48 70,000 D M
17 Feb, 2026 Helen Louise Collins Common Stock D 45,000 $26.17 25,000 D S